• 1. Base for Drug Clinical Trial, West China Hospital of Sichuan University, Chengdu 610041, China2. Chongqing Fujin Biology and Medicine Company, Chongqing 410041, China;
ZHENG Li, Email: lzheng2005618@yahoo.com.cn
Export PDF Favorites Scan Get Citation

Objective To evaluate the safety and tolerance of pegfilgrastin (PEG-G-CSF) in Chinese healthy volunteers.
Methods Thirty healthy volunteers were randomly divided into five single-dose groups to receive PEG-G-CSF 15, 30, 50, 60 or 75μg/kg by hypodermic injection. The safety profile and tolerability were evaluated by observing symptoms, vital signs, laboratory tests and electro cardiogram.
Results No serious adverse event was reported for any volunteer. Transient dizziness occurred in one person in the 50 μg/kg dose group, and mild dizziness and ostalgia was found in all six people in the 75μg/kg dose group, of whom one experienced transient fever and two experienced mild diarrhea. No clinically significant changes in laboratory tests and electrocardiogram were found during the follow-up period.
Conclusions The maximum tolerated dose of PEG-G-CSF injection in Chinese healthy volunteers is 60 μg/kg. Doses below 60μg/kg can be well tolerated. The recommended dose for phase II clinical trials is 60 μg/kgone, one dose for each cycle of chemotherapy.

Citation: ZHENG Li,XU Nan,LIU Chuntao,WANG Ying,LUO Zhu,LUO Hua. Tolerability of Hypodermic Injection of Pegfilgrastin (PEG-G-CSF) in a Phase I Study. Chinese Journal of Evidence-Based Medicine, 2008, 08(3): 155-158. doi: 10.7507/1672-2531.20080035 Copy

  • Previous Article

    CONSORT Serial 1: How to Explain the Methodological Rationale of Randomized Controlled Trial on Traditional Chinese Medicine?
  • Next Article

    Observation of Clinical Efficacy of Ultrasonic Atomization of Penicillin Combined with Erythromycin in Children with Acute Suppurative Tonsillitis